ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0714

Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort

Alvaro Oyarce-Calderón1, Allison Figueroa-Sánchez2, Leonor León-Yaurimucha2, Rocío Gamboa-Cárdenas3, Zoila Rodríguez-Bellido4, Risto Perich-Campos5, Graciela Alarcón6, Manuel Ugarte-Gil7 and Victor Pimentel-Quiroz8, 1Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, 2Universidad Científica del Sur, Lima, Peru, 3Universidad Científica del Sur, Lima, Peru, 4Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 6The University of Alabama at Birmingham, Oakland, CA, 7Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 8Universidad Científica del Sur, San Isidro, Peru

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Anxiety, depression, risk factors, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and their associated factors remain to be identified at global level. The aim of this study is to determine the factors associated with depression and anxiety in AAV patients from a Latin American cohort.

Methods: Patients from a single-center Peruvian AAV cohort [the Almenara Vasculitis cohort] were included. Depression symptoms were assessed by the Patient Health Questionnaire-9 (PHQ-9) questionnaire whereas anxiety symptoms were assessed by the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. For both questionnaires, the higher the score, the greater the intensity of the corresponding symptoms: GAD-7 ranges from 0 to 21 while PHQ-9 ranges from 0 to 27. Potential associated factors were sex, age, ethnicity, educational level, relationship status, employment and socioeconomic status (SES), disease activity, erythrocyte sedimentation rate level, C-reactive protein level, ANCA status, glucocorticoid use and doses, immunosuppressive (IS) use and type, diagnosis and the AAV-Patient reported outcome (PRO) questionnaire domains. Cross-sectional univariable and multivariable linear regression models were performed. The multivariable models were done using a backward selection procedure with an alpha to stay in the model of 0.05.

Results: Eighty-eight patients were included; 49 (69%) were female and their mean age at diagnosis was 61.4 (13) years. The GAD-7 and the PHQ-9 scores at baseline were 6.3 (4.3) and 7.2 (4.9), respectively. In multivariable analysis, middle SES, active disease, and the social and emotional impact domain of the AAV-PRO were negatively associated with anxious symptoms. On the other hand, low SES, relapsing and active disease, and organ-specific symptoms and the social and emotional impact domains of the AAV-PRO were negatively associated with depressive symptoms.

Conclusion: A middle-low SES, relapsing and active disease, and some domains from the AAV-PRO (social and emotional impact, organ-specific symptoms) were associated with higher intensity of anxiety and depression symptoms. Further studies are needed to evaluate these findings in other populations and seek better strategies to improve depression and anxiety symptoms in AAV patients.

Supporting image 1Table 1: Factors associated with depression symptoms as assessed by the PHQ-9 questionnaire.

Supporting image 2Table 2: Factors associated with anxiety symptoms as assessed by the GAD-7 questionnaire.


Disclosures: A. Oyarce-Calderón: None; A. Figueroa-Sánchez: None; L. León-Yaurimucha: None; R. Gamboa-Cárdenas: None; Z. Rodríguez-Bellido: None; R. Perich-Campos: None; G. Alarcón: None; M. Ugarte-Gil: AstraZeneca, 2, 6, Ferrer, 2, 6, GSK, 2, 6, Johnson & Johnson, 5, Novartis, 2, 6, Tecnofarma, 2, 6; V. Pimentel-Quiroz: Biopas, 6, Pfizer, 6, Roche, 6, technofarm, 6.

To cite this abstract in AMA style:

Oyarce-Calderón A, Figueroa-Sánchez A, León-Yaurimucha L, Gamboa-Cárdenas R, Rodríguez-Bellido Z, Perich-Campos R, Alarcón G, Ugarte-Gil M, Pimentel-Quiroz V. Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-depression-and-anxiety-in-anca-associated-vasculitis-patients-data-from-the-almenara-vasculitis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-depression-and-anxiety-in-anca-associated-vasculitis-patients-data-from-the-almenara-vasculitis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology